» Articles » PMID: 34885030

In Vivo Targeting of CXCR4-New Horizons

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Dec 10
PMID 34885030
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Given its pre-eminent role in the context of tumor cell growth as well as metastasis, the C-X-C motif chemokine receptor 4 (CXCR4) has attracted a lot of interest in the field of nuclear oncology, and clinical evidence on the high potential of CXCR4-targeted theranostics is constantly accumulating. Additionally, since CXCR4 also represents a key player in the orchestration of inflammatory responses to inflammatory stimuli, based on its expression on a variety of pro- and anti-inflammatory immune cells (e.g., macrophages and T-cells), CXCR4-targeted inflammation imaging has recently gained considerable attention. Therefore, after briefly summarizing the current clinical status quo of CXCR4-targeted theranostics in cancer, this review primarily focuses on imaging of a broad spectrum of inflammatory diseases via the quantification of tissue infiltration with CXCR4-expressing immune cells. An up-to-date overview of the ongoing preclinical and clinical efforts to visualize inflammation and its resolution over time is provided, and the predictive value of the CXCR4-associated imaging signal for disease outcome is discussed. Since the sensitivity and specificity of CXCR4-targeted immune cell imaging greatly relies on the availability of suitable, tailored imaging probes, recent developments in the field of CXCR4-targeted imaging agents for various applications are also addressed.

Citing Articles

Validation of the C-X-C chemokine receptor 3 (CXCR3) as a target for PET imaging of T cell activation.

Martin S, Wendlinger L, Zitti B, Hicham M, Postupalenko V, Marx L EJNMMI Res. 2024; 14(1):77.

PMID: 39196448 PMC: 11358572. DOI: 10.1186/s13550-024-01142-1.


Chemokine receptor PET imaging: Bridging molecular insights with clinical applications.

Hunter C, Larimer B Nucl Med Biol. 2024; 134-135:108912.

PMID: 38691942 PMC: 11180593. DOI: 10.1016/j.nucmedbio.2024.108912.


Synergistic Anticancer Activity of Plumbagin and Xanthohumol Combination on Pancreatic Cancer Models.

Palanisamy R, Indrajith Kahingalage N, Archibald D, Casari I, Falasca M Int J Mol Sci. 2024; 25(4).

PMID: 38397018 PMC: 10888694. DOI: 10.3390/ijms25042340.


CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges.

Werner R, Haug A, Buske C, Heidegger S, Illert A, Bassermann F Nuklearmedizin. 2024; 63(2):57-61.

PMID: 38190998 PMC: 10963126. DOI: 10.1055/a-2194-9965.


C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Hematological Malignancies-Myeloablative Effects, Antilymphoma Activity, and Safety Profile.

Dreher N, Dorrler A, Kraus S, Higuchi T, Serfling S, Samnick S Clin Nucl Med. 2023; 49(2):146-151.

PMID: 38081189 PMC: 11441726. DOI: 10.1097/RLU.0000000000004974.


References
1.
Luo Y, Cao X, Pan Q, Li J, Feng J, Li F . Ga-Pentixafor PET/CT for Imaging of Chemokine Receptor 4 Expression in Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to F-FDG PET/CT. J Nucl Med. 2019; 60(12):1724-1729. PMC: 6894383. DOI: 10.2967/jnumed.119.226134. View

2.
Werner R, Weich A, Higuchi T, Schmid J, Schirbel A, Lassmann M . Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach. Theranostics. 2017; 7(6):1489-1498. PMC: 5436508. DOI: 10.7150/thno.18754. View

3.
Borchert T, Beitar L, Langer L, Polyak A, Wester H, Ross T . Dissecting the target leukocyte subpopulations of clinically relevant inflammation radiopharmaceuticals. J Nucl Cardiol. 2019; 28(4):1636-1645. DOI: 10.1007/s12350-019-01929-z. View

4.
Wang Y, Dembowsky K, Chevalier E, Stuve P, Korf-Klingebiel M, Lochner M . C-X-C Motif Chemokine Receptor 4 Blockade Promotes Tissue Repair After Myocardial Infarction by Enhancing Regulatory T Cell Mobilization and Immune-Regulatory Function. Circulation. 2019; 139(15):1798-1812. PMC: 6467561. DOI: 10.1161/CIRCULATIONAHA.118.036053. View

5.
Bosma S, van Driel P, Hogendoorn P, Dijkstra P, Sier C . Introducing fluorescence guided surgery into orthopedic oncology: A systematic review of candidate protein targets for Ewing sarcoma. J Surg Oncol. 2018; 118(6):906-914. PMC: 6220824. DOI: 10.1002/jso.25224. View